Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’s disease
10 mai 2021 08h30 HE
|
Cassava Sciences, Inc.
- Randomized, Controlled Study is Designed to Evaluate Cognition in Patients Who Continue Versus Discontinue Simufilam Over Six Months – - Target Enrollment is 100 Study Participants - AUSTIN,...
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
27 avr. 2021 08h30 HE
|
Cassava Sciences, Inc.
AUSTIN, Texas, April 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been...
Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum
26 avr. 2021 08h30 HE
|
Cassava Sciences, Inc.
AUSTIN, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been...
Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release
21 avr. 2021 08h30 HE
|
Cassava Sciences, Inc.
- 9 Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference in July 2021 as an Oral Presentation - - Initiation of Pivotal Phase 3 Program Remains On-track for 2nd...
Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights
23 mars 2021 08h30 HE
|
Cassava Sciences, Inc.
AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for...
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
09 mars 2021 09h00 HE
|
Cassava Sciences, Inc.
AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced...
Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
08 mars 2021 08h30 HE
|
Cassava Sciences, Inc.
AUSTIN, Texas, March 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been...
Cassava Sciences to Present at SVB Leerink Global Healthcare Conference
23 févr. 2021 08h30 HE
|
Cassava Sciences, Inc.
AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited...
Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease
22 févr. 2021 08h30 HE
|
Cassava Sciences, Inc.
- Two Upcoming Phase 3 Studies and a Previously Completed Phase 2 Program Support a New Drug Application Filing for Simufilam in Alzheimer’s disease - - Agreement Reached to Use ADAS-Cog as...
Cassava Sciences Announces Closing of $200 Million Registered Direct Offering
12 févr. 2021 17h08 HE
|
Cassava Sciences, Inc.
AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease,...